INTRODUCTION The Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) is a powerful prognostic tool validated in multiple Western populations. However, its utility in the young Middle Eastern population is unknown. METHODOLOGY We conducted a retrospective analysis of 152 unselected patients with chronic lymphocytic leukemia (CLL) diagnosed between 2008 and 2022 at the Kuwait Cancer Control Center, which serves as the sole cancer center in Kuwait. The evaluation of the CLL-IPI was based on the assessment of event-free survival (EFS) across the entire cohort. Subsequently, we compared the CLL-IPI with the International Prognostic Score for Early-stage patients (IPS-E) in order to predict the time to first treatment specifically within the subgroup of patients diagnosed with early-stage disease. RESULTS The median age of the study cohort was 59.9 years (IQR, 53.1-68.8). The 5-year EFS rates for the low, intermediate, and high/very high-risk categories were approximately 82%, 34%, and 23%, respectively, p < 0.001 (C-statistic = 0.67). On multivariate analysis, advanced stage and unmated IGHV status were independent prognostic factors of EFS. In those with early-stage disease, cumulative 5-year treatment incidence rates for the low, intermediate, and high/very high-risk categories based on the CLL-IPI score were approximately 8%, 55%, and 55%, respectively, p = 0.001 (C-statistic = 0.70). However, based on the IPS-E score, the cumulative 5-year treatment incidence rates for the low, intermediate, and high-risk categories were approximately 0%, 10%, and 60%, respectively, p < 0.001 (C-statistic = 0.73). CONCLUSIONS The CLL-IPI and the IPS-E are valid stratification tool in our young Middle Eastern population.

中文翻译：

---

中东地区年轻慢性淋巴细胞白血病人群的 CLL-IPI 和 IPS-E 预后指数评估：科威特癌症控制中心的回顾性分析。

简介 慢性淋巴细胞白血病国际预后指数 (CLL-IPI) 是一种强大的预后工具，已在多个西方人群中得到验证。然而，它在中东年轻人中的效用尚不清楚。我们对 2008 年至 2022 年间在科威特癌症控制中心（科威特唯一的癌症中心）诊断的 152 名未经选择的慢性淋巴细胞白血病 (CLL) 患者进行了回顾性分析。CLL-IPI 的评估基于整个队列的无事件生存期 (EFS) 评估。随后，我们将 CLL-IPI 与早期患者国际预后评分 (IPS-E) 进行比较，以预测诊断为早期疾病的患者亚组中首次治疗的时间。结果 研究队列的中位年龄为 59.9 岁（IQR，53.1-68.8）。低、中、高/极高风险类别的 5 年 EFS 率分别约为 82%、34% 和 23%，p < 0.001（C 统计量 = 0.67）。多变量分析显示，晚期和未交配 IGHV 状态是 EFS 的独立预后因素。在早期疾病患者中，基于 CLL-IPI 评分的低、中、高/极高风险类别的累积 5 年治疗发生率分别约为 8%、55% 和 55%。 p = 0.001（C 统计量 = 0.70）。然而，根据 IPS-E 评分，低、中、高风险类别的 5 年累积治疗发生率分别约为 0%、10% 和 60%，p < 0.001（C 统计= 0.73）。结论 CLL-IPI 和 IPS-E 是中东年轻人的有效分层工具。